| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J W Y Yuen, C Wu, C K Wang, D D Kim, R M Procyshyn, W G Honer, A M Bar. A comparison of the effects of clozapine and its metabolite norclozapine on metabolic dysregulation in rodent models. Neuropharmacology. vol 175. 2021-09-23. PMID:31348941. |
the second generation antipsychotic drug clozapine is a psychotherapeutic agent with superior efficacy for treatment-resistant schizophrenia. |
2021-09-23 |
2023-08-13 |
Not clear |
| Sharon Taub, Moshe Hoshen, Ran Balicer, Shiri Kamhi-Nesher, Abraham Weizman, Amir Krivo. Metabolic predictors for mortality among patients treated with long-term clozapine - A longitudinal study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 41. 2021-09-23. PMID:32981820. |
in this study we aimed to explore predictors for mortality in a large cohort of schizophrenia patients treated with long-term clozapine, using the electronic medical records of the largest health care provider in israel. |
2021-09-23 |
2023-08-13 |
Not clear |
| John Lally, Emily Breese, Mugtaba Osman, Cai Hua Sim, Hitesh Shetty, Amir Krivoy, James H MacCab. Augmentation of clozapine with ECT: a retrospective case analysis. Acta neuropsychiatrica. vol 33. issue 1. 2021-09-20. PMID:32967745. |
we sought to assess the effectiveness of clozapine augmentation with electroconvulsive therapy (ect) (c+ect) in patients with clozapine-resistant schizophrenia. |
2021-09-20 |
2023-08-13 |
Not clear |
| Yumiko Akamine, Yuka Kikuchi, Masatomo Miur. Effects on monotherapy and reduction of antipsychotic drugs by clozapine therapy in Japanese patients with treatment-resistant schizophrenia. Journal of clinical pharmacy and therapeutics. vol 46. issue 5. 2021-09-16. PMID:33959995. |
effects on monotherapy and reduction of antipsychotic drugs by clozapine therapy in japanese patients with treatment-resistant schizophrenia. |
2021-09-16 |
2023-08-13 |
Not clear |
| Yumiko Akamine, Yuka Kikuchi, Masatomo Miur. Effects on monotherapy and reduction of antipsychotic drugs by clozapine therapy in Japanese patients with treatment-resistant schizophrenia. Journal of clinical pharmacy and therapeutics. vol 46. issue 5. 2021-09-16. PMID:33959995. |
the schizophrenia guidelines in japan and many other countries describe clozapine as the first-choice drug for patients with treatment-resistant schizophrenia. |
2021-09-16 |
2023-08-13 |
Not clear |
| Elisa Pallares Vela, Prashil Dave, Ivan Cancarevi. Clozapine-Related Thromboembolic Events. Cureus. vol 13. issue 8. 2021-09-14. PMID:34513458. |
clozapine is an atypical antipsychotic used for treatment-resistant schizophrenia. |
2021-09-14 |
2023-08-13 |
Not clear |
| Subho Chakrabart. Clozapine resistant schizophrenia: Newer avenues of management. World journal of psychiatry. vol 11. issue 8. 2021-09-14. PMID:34513606. |
clozapine resistant schizophrenia: newer avenues of management. |
2021-09-14 |
2023-08-13 |
Not clear |
| Subho Chakrabart. Clozapine resistant schizophrenia: Newer avenues of management. World journal of psychiatry. vol 11. issue 8. 2021-09-14. PMID:34513606. |
about 40%-70% of the patients with treatment-resistant schizophrenia have a poor response to adequate treatment with clozapine. |
2021-09-14 |
2023-08-13 |
Not clear |
| Nathan Gilbreth, Hari Nath, Fernando Quesada, Delatre Lol. Clozapine-Induced Pericardial Effusion Presenting with Persistent Tachycardia. Case reports in medicine. vol 2021. 2021-09-10. PMID:34497649. |
clozapine is an atypical antipsychotic used in refractory schizophrenia and depression. |
2021-09-10 |
2023-08-13 |
Not clear |
| Marek Krzystanek, Marek Asman, Joanna Witecka, Artur Pałasz, Ryszard Wiaderkiewic. Selected single-nucleotide variants in GRIN1, GRIN2A, and GRIN2B encoding subunits of the NMDA receptor are not biomarkers of schizophrenia resistant to clozapine: exploratory study. Pharmacological reports : PR. vol 73. issue 1. 2021-09-08. PMID:33025395. |
selected single-nucleotide variants in grin1, grin2a, and grin2b encoding subunits of the nmda receptor are not biomarkers of schizophrenia resistant to clozapine: exploratory study. |
2021-09-08 |
2023-08-13 |
Not clear |
| Graham Blackman, Jenny E L Lisshammar, Rayyan Zafar, Thomas A Pollak, Megan Pritchard, Alexis E Cullen, Jonathan Rogers, Ben Carter, Kira Griffiths, Matthew Nour, Anthony S David, Philip McGuire, Robert Stewart, James MacCab. Clozapine Response in Schizophrenia and Hematological Changes. Journal of clinical psychopharmacology. vol 41. issue 1. 2021-09-07. PMID:33347018. |
clozapine response in schizophrenia and hematological changes. |
2021-09-07 |
2023-08-13 |
Not clear |
| Graham Blackman, Jenny E L Lisshammar, Rayyan Zafar, Thomas A Pollak, Megan Pritchard, Alexis E Cullen, Jonathan Rogers, Ben Carter, Kira Griffiths, Matthew Nour, Anthony S David, Philip McGuire, Robert Stewart, James MacCab. Clozapine Response in Schizophrenia and Hematological Changes. Journal of clinical psychopharmacology. vol 41. issue 1. 2021-09-07. PMID:33347018. |
clozapine is the only effective medication for treatment-resistant schizophrenia; however, its mechanism of action remains unclear. |
2021-09-07 |
2023-08-13 |
Not clear |
| Meha Verma, Sandeep Grover, Subho Chakrabart. Cost of the Illness of Treatment-Resistant Schizophrenia: A Mirror Image Study Comparing Clozapine With Other Antipsychotics. Journal of clinical psychopharmacology. vol 41. issue 1. 2021-09-07. PMID:33347021. |
cost of the illness of treatment-resistant schizophrenia: a mirror image study comparing clozapine with other antipsychotics. |
2021-09-07 |
2023-08-13 |
Not clear |
| Meha Verma, Sandeep Grover, Subho Chakrabart. Cost of the Illness of Treatment-Resistant Schizophrenia: A Mirror Image Study Comparing Clozapine With Other Antipsychotics. Journal of clinical psychopharmacology. vol 41. issue 1. 2021-09-07. PMID:33347021. |
this study aimed to evaluate and compare the cost of illness in patients with treatment-resistant schizophrenia (trs) during 3 months before starting clozapine and for the initial 3 months of treatment with clozapine. |
2021-09-07 |
2023-08-13 |
Not clear |
| Michael Shuman, Lori Moss, Adam Dilic. Never Say Never: Successful Clozapine Rechallenge After Multiple Episodes of Neutropenia. Focus (American Psychiatric Publishing). vol 19. issue 1. 2021-09-07. PMID:34483771. |
clozapine is a second-generation antipsychotic with a superior efficacy for the management of treatment-resistant schizophrenia but underutilized because of potential side effects. |
2021-09-07 |
2023-08-13 |
Not clear |
| Olaoluwa O Okusaga, Brian G Mitchell, Jared D Bernard, Annette Walde. Clozapine Is Associated With Higher COVID-19 Infection Rate in Veterans With Schizophrenia or Schizoaffective Disorder. The Journal of clinical psychiatry. vol 82. issue 5. 2021-09-02. PMID:34428355. |
clozapine is associated with higher covid-19 infection rate in veterans with schizophrenia or schizoaffective disorder. |
2021-09-02 |
2023-08-13 |
Not clear |
| Sarah L Kopelovich, Keith Wood, Robert O Cotes, David R Goldsmit. Integration of Clozapine-associated Harm Obsessions into Cognitive Behavioral Conceptualization and Treatment Planning for Thought Broadcasting: A Case Study. Journal of psychiatric practice. vol 26. issue 4. 2021-09-01. PMID:32692132. |
clozapine has demonstrated superior efficacy for the treatment of medication-resistant schizophrenia but it is also associated with an increased risk for ocs. |
2021-09-01 |
2023-08-13 |
Not clear |
| Giulia Tronchin, Theophilus N Akudjedu, Mohamed Ahmed, Laurena Holleran, Brian Hallahan, Dara M Cannon, Colm McDonal. Correction to: Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 46. issue 10. 2021-09-01. PMID:34168280. |
correction to: progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. |
2021-09-01 |
2023-08-13 |
Not clear |
| Seong Hoon Jeong, Yong Sik Ki. Challenges in Prescribing Clozapine in the Era of COVID-19: A Review Focused on Immunological Implications. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 19. issue 3. 2021-09-01. PMID:34294611. |
schizophrenia has been considered to have a deep connection with the immune system, and clozapine can induce further changes in this system. |
2021-09-01 |
2023-08-13 |
Not clear |
| Selene R T Veerman, Jan P A M Bogers, Dan Cohen, Peter F J Schult. COVID-19: Risks, Complications, and Monitoring in Patients on Clozapine. Pharmacopsychiatry. 2021-09-01. PMID:34470068. |
schizophrenia patients in general and clozapine users in particular belong to a high-risk group that warrants early vaccination on a medical indication. |
2021-09-01 |
2023-08-13 |
Not clear |